Published • loading... • Updated
Philip Ashton-Rickardt Debunks 5 Myths About Biotech and Brain Disease Research
Ashton-Rickardt says most drug breakthroughs take more than 10 years and often begin in small teams that adapt as data changes.
- According to the Biotechnology Innovation Organization, the average drug development timeline can exceed 10 years, with Ashton-Rickardt noting that biotech progress takes years, not overnight despite media headlines suggesting immediate breakthroughs.
- Understanding Neurodegenerative diseases like ALS requires looking beyond neurons alone; Inflammation inside the brain is increasingly recognized as a key factor in disease progression, driving Ashton-Rickardt's focus on engineered immune cell therapies.
- Myth 3 suggests larger companies innovate faster due to resources, but smaller research groups often drive major Innovation; Practical tip: do not judge Innovation by company size alone.
- Scientific leadership requires communication, adaptability, and operational discipline beyond expertise alone, as Ashton-Rickardt emphasizes that leadership became increasingly about people, patience, and management skills over time.
- "Meaningful progress usually takes longer than expected," Ashton-Rickardt says, as long-term success depends on constant learning and adaptability; Breakthroughs come from years of disciplined work, not singular events.
Insights by Ground AI
89 Articles
89 Articles
abc12/WJRT+88 Reposted by 88 other sources
Philip Ashton-Rickardt Debunks 5 Myths About Biotech and Brain Disease Research
·Flint, United States
Read Full ArticleCoverage Details
Total News Sources89
Leaning Left11Leaning Right7Center37Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 20%
C 67%
13%
Factuality
To view factuality data please Upgrade to Premium
